Do analysts rate MBRX or SILO?

Moleculin Biotech presently has a consensus price target of $3.00, indicating a potential upside of 710.59%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ENSC or SILO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate TRAW or SILO?

Traws Pharma presently has a consensus price target of $1.00, indicating a potential upside of 148.08%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Traws Pharma is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TRAW or SILO more profitable?

Traws Pharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -23,868.92% -165.52% Silo Pharma -6,726.39% -81.75% -66.35%

Do analysts recommend SILO or OBSV?

Given ObsEva's higher probable upside, analysts plainly believe ObsEva is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, SILO or OBSV?

Silo Pharma has higher revenue and earnings than ObsEva. Silo Pharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silo Pharma $54.08K 35.24 -$4.23M -$4.36 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is SILO or OBSV more profitable?

ObsEva has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Silo Pharma -6,726.39% -81.75% -66.35% ObsEva N/A -416.36% -92.01%

Do analysts recommend SILO or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Silo Pharma (SILO) Competitors

$1.20 0.00 (0.00%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.08%)

As of 07:00 AM Eastern

Compare

SILO vs. MBRX, ENSC, TRAW, OBSV, and CURX

Should you buy Silo Pharma stock or one of its competitors? Silo Pharma's main competitors and comparable companies include Moleculin Biotech (MBRX), Ensysce Biosciences (ENSC), Traws Pharma (TRAW), ObsEva (OBSV), and Curanex Pharmaceuticals (CURX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Silo Pharma compare to Moleculin Biotech?

Moleculin Biotech (NASDAQ:MBRX) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Moleculin Biotech has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Silo Pharma has higher revenue and earnings than Moleculin Biotech. Silo Pharma is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Silo Pharma	$54.08K	35.24	-$4.23M	-$4.36	N/A

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 18.0% of Moleculin Biotech shares are owned by company insiders. Comparatively, 3.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Silo Pharma had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 2 mentions for Silo Pharma and 1 mentions for Moleculin Biotech. Silo Pharma's average media sentiment score of 1.66 beat Moleculin Biotech's score of 1.37 indicating that Silo Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Positive
Silo Pharma	Very Positive

Moleculin Biotech presently has a consensus price target of $3.00, indicating a potential upside of 710.59%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Moleculin Biotech has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

Moleculin Biotech beats Silo Pharma on 8 of the 14 factors compared between the two stocks.

How does Silo Pharma compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Silo Pharma has higher revenue and earnings than Ensysce Biosciences. Silo Pharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	N/A	N/A	-$10.18M	-$2.76	N/A
Silo Pharma	$54.08K	35.24	-$4.23M	-$4.36	N/A

In the previous week, Silo Pharma had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 2 mentions for Silo Pharma and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 1.79 beat Silo Pharma's score of 1.66 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Ensysce Biosciences	Very Positive
Silo Pharma	Very Positive

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ensysce Biosciences has a net margin of -280.53% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ensysce Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Silo Pharma has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

Ensysce Biosciences and Silo Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Silo Pharma compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Traws Pharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-23,868.92%	-165.52%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Traws Pharma has higher revenue and earnings than Silo Pharma. Silo Pharma is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.22	$9.17M	-$1.74	N/A
Silo Pharma	$54.08K	35.24	-$4.23M	-$4.36	N/A

In the previous week, Silo Pharma had 1 more articles in the media than Traws Pharma. MarketBeat recorded 2 mentions for Silo Pharma and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.82 beat Silo Pharma's score of 1.66 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Very Positive
Silo Pharma	Very Positive

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 7.6% of Traws Pharma shares are held by company insiders. Comparatively, 3.6% of Silo Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Traws Pharma has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Traws Pharma presently has a consensus price target of $1.00, indicating a potential upside of 148.08%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Traws Pharma is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Traws Pharma beats Silo Pharma on 10 of the 14 factors compared between the two stocks.

How does Silo Pharma compare to ObsEva?

Silo Pharma (NASDAQ:SILO) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ObsEva has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
ObsEva	N/A	-416.36%	-92.01%

Silo Pharma has higher revenue and earnings than ObsEva. Silo Pharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$54.08K	35.24	-$4.23M	-$4.36	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Silo Pharma has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, Silo Pharma had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Silo Pharma and 0 mentions for ObsEva. Silo Pharma's average media sentiment score of 1.66 beat ObsEva's score of 0.00 indicating that Silo Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Silo Pharma	Very Positive
ObsEva	Neutral

Given ObsEva's higher probable upside, analysts plainly believe ObsEva is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Silo Pharma beats ObsEva on 8 of the 14 factors compared between the two stocks.

How does Silo Pharma compare to Curanex Pharmaceuticals?

Silo Pharma (NASDAQ:SILO) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Silo Pharma had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 2 mentions for Silo Pharma and 1 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.79 beat Silo Pharma's score of 1.66 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Silo Pharma	Very Positive
Curanex Pharmaceuticals	Very Positive

5.6% of Silo Pharma shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Silo Pharma. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$54.08K	35.24	-$4.23M	-$4.36	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Silo Pharma has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.88, suggesting that its share price is 388% less volatile than the broader market.

Curanex Pharmaceuticals has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Summary

Silo Pharma beats Curanex Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Silo Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SILO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SILO vs. The Competition

Export

Metric	Silo Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.91M	$12.46B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	-0.28	665.35	215.94	21.15
Price / Sales	35.24	933.07	625.89	104.29
Price / Cash	N/A	83.43	76.19	51.56
Price / Book	0.17	9.25	10.40	6.01
Net Income	-$4.23M	$2.84B	$3.50B	$380.68M
7 Day Performance	-18.37%	-3.82%	-3.32%	-3.16%
1 Month Performance	-31.82%	-7.00%	-6.58%	-5.20%
1 Year Performance	-86.71%	-4.67%	2.68%	-4.08%

Silo Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SILO Silo Pharma	0.7795 of 5 stars	$1.20 flat	N/A	-87.9%	$1.91M	$54.08K	N/A	3
MBRX Moleculin Biotech	3.6238 of 5 stars	$0.44 -1.5%	$3.00 +583.5%	-97.1%	$8.68M	N/A	N/A	17	Analyst Forecast Gap Up
ENSC Ensysce Biosciences	1.5007 of 5 stars	$0.43 -0.1%	N/A	-75.8%	$8.36M	$5.07M	N/A	10	Positive News
TRAW Traws Pharma	2.144 of 5 stars	$0.48 -7.9%	$1.00 +108.8%	-85.8%	$7.99M	$2.79M	N/A	7
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SILO) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silo Pharma (SILO) Competitors

SILO vs. MBRX, ENSC, TRAW, OBSV, and CURX

How does Silo Pharma compare to Moleculin Biotech?

Summary

How does Silo Pharma compare to Ensysce Biosciences?

Summary

How does Silo Pharma compare to Traws Pharma?

Summary

How does Silo Pharma compare to ObsEva?

Summary

How does Silo Pharma compare to Curanex Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO vs. The Competition

Silo Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silo Pharma (SILO) Competitors

SILO vs. MBRX, ENSC, TRAW, OBSV, and CURX

How does Silo Pharma compare to Moleculin Biotech?

Is MBRX or SILO more profitable?

Which has stronger valuation & earnings, MBRX or SILO?

Do institutionals & insiders believe in MBRX or SILO?

Does the media favor MBRX or SILO?

Do analysts rate MBRX or SILO?

Which has more risk and volatility, MBRX or SILO?

Summary

How does Silo Pharma compare to Ensysce Biosciences?

Which has better earnings and valuation, ENSC or SILO?

Does the media favor ENSC or SILO?

Do institutionals and insiders believe in ENSC or SILO?

Is ENSC or SILO more profitable?

Do analysts rate ENSC or SILO?

Which has more volatility and risk, ENSC or SILO?

Summary

How does Silo Pharma compare to Traws Pharma?

Is TRAW or SILO more profitable?

Which has higher valuation and earnings, TRAW or SILO?

Does the media favor TRAW or SILO?

Do insiders and institutionals have more ownership in TRAW or SILO?

Which has more risk & volatility, TRAW or SILO?

Do analysts rate TRAW or SILO?

Summary

How does Silo Pharma compare to ObsEva?

Do institutionals & insiders have more ownership in SILO or OBSV?

Is SILO or OBSV more profitable?

Which has better valuation & earnings, SILO or OBSV?

Which has more volatility & risk, SILO or OBSV?

Does the media prefer SILO or OBSV?

Do analysts recommend SILO or OBSV?

Summary

How does Silo Pharma compare to Curanex Pharmaceuticals?

Do analysts recommend SILO or CURX?

Does the media refer more to SILO or CURX?

Do institutionals and insiders hold more shares of SILO or CURX?

Which has preferable valuation and earnings, SILO or CURX?

Which has more volatility and risk, SILO or CURX?

Is SILO or CURX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO vs. The Competition

Silo Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools